Research Article
Blood Level Omega-3 Fatty Acids as Risk Determinant Molecular Biomarker for Prostate Cancer
Table 3
Blood level omega-3 Polyunsaturated fatty acids versus advanced prostate risk random effect analysis model.
| Groups | | Heterogeneity | Effect estimates and 95% confidence interval | Publication bias | Omega-3 derivatives |
Number of study | value | df | value | | Point estimates | Lower limit | Upper limit | value | Begg | Egger |
| ALA | 3 | 0.654 | 2 | 0.721 | 0.000 | 0.965 | 0.576 | 1.618 | 0.893 | 0.296 | 0.051 | DHA | 4 | 2.289 | 3 | 0.515 | 0.000 | 0.896 | 0.640 | 1.256 | 0.524 | 1.000 | 0.342 | DPA | 3 | 0.367 | 2 | 0.832 | 0.000 | 0.870 | 0.514 | 1.473 | 0.606 | 1.000 | 0.618 | EPA | 4 | 6.180 | 3 | 0.103 | 41.457 | 0.975 | 0.582 | 1.634 | 0.925 | 0.308 | 0.309 | (DHA + DPA + EPA)* | | 8.870 | 10 | 0.545 | 0.000 | 0.908 | 0.708 | 1.164 | 0.447 | | | (DHA + EPA)* | | 8.482 | 7 | 0.292 | 17.471 | 0.919 | 0.693 | 1.219 | 0.559 | | | Total omega-3* | | 9.580 | 13 | 0.728 | 0.000 | 0.919 | 0.734 | 1.149 | 0.457 | | |
|
|
*Generated from total effect estimates from each PUFA random effect analysis.
|